Literature DB >> 8127966

[Sonography of the infant hip. Sources of error, progress and current clinical relevance].

R Graf1, C Tschauner.   

Abstract

Effective prevention of late dysplastic dislocation of the hip (DDH) has become a reality since reliable diagnosis has been possible at an early stage by means of the original sonographic method according to Graf. A correct sonographic diagnosis must be instantly followed by adequate, biomechanically rational, and consistent therapeutic management and long-term follow-up. The results of a strictly comparative follow-up study emphasize the enormous progress in the quality of therapeutic results gained when routine sonographic newborn hip "screening" is performed directly in the maternity wards: successful anatomical healing with conservative treatment is regularly obtained without femoral head necrosis, without surgery and without late DDH, and costs less when sonographic assessment is done within the first days of life. For this reason, the Austrian government has included sonographic neonatal hip screening in its general health prevention program-and also reimbursed the cost of this preventive procedure-since 1992.

Entities:  

Mesh:

Year:  1994        PMID: 8127966

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

1.  [Paediatric hip sonography: current status at German university hospitals].

Authors:  C-D Peterlein; S Fuchs-Winkelmann
Journal:  Orthopade       Date:  2014-02       Impact factor: 1.087

2.  Long-term results of a nationwide general ultrasound screening system for developmental disorders of the hip: the Austrian hip screening program.

Authors:  Christoph Thallinger; Renata Pospischill; Rudolf Ganger; Christof Radler; Christoph Krall; Franz Grill
Journal:  J Child Orthop       Date:  2014-01-22       Impact factor: 1.548

3.  [When is the optimal time for hip ultrasound screening?].

Authors:  S Farr; F Grill; D Müller
Journal:  Orthopade       Date:  2008-06       Impact factor: 1.004

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.